Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA ® Reported at ESMO Phase 1 Data for IMGN779 and IMGN632 to be Presented in Oral Sessions at ASH Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting
Phase 1 Data for IMGN779 and IMGN632 to be Highlighted in Oral Presentations at ASH WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts
View HTML
Toggle Summary ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
Preliminary Data Demonstrate Favorable Safety Profile and Encouraging Activity in Heavily Pretreated Patients with Ovarian Cancer WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, November 2, 2018 to discuss its
View HTML
Toggle Summary ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 27, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 31, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference .
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA Encouraging Combination Data Reported from FORWARD II Expansion Cohort of Mirvetuximab with Avastin ® ; Initial Data from Expansion Cohort in Combination with Keytruda ® to be Presented at ESMO $163 Million Net Proceeds from Public
View HTML